Hormone Refractory Prostate Cancer Clinical Trials

59 clinical trials for Hormone Refractory Prostate Cancer across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer — RECRUITING · PHASE1
• Non-interventional study for recording the treatment and the influence on the treatment-specific quality of life with patients with hormone-refractory prostate cancer under a Docetaxel (Eurotere®) containing chemotherapy. — RECRUITING
• An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001 — COMPLETED · PHASE2
• A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-free or mildly symptomatic patients with prostate cancer and bone metastases, who have rising serum prostate specific antigen (PSA) levels despite medical or surgical castration — COMPLETED · PHASE2
• An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-003 — COMPLETED · PHASE2
• A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy — COMPLETED · PHASE2
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE4
• A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases — COMPLETED · PHASE3
• The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment — ACTIVE_NOT_RECRUITING · PHASE2
• Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) — COMPLETED · PHASE1
• Study Evaluating the Safety and Tolerability of L-377202 — COMPLETED · PHASE1
• Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer — COMPLETED · PHASE2
• BAY88-8223, Does Response Study in HRPC Patients — COMPLETED · PHASE2
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer — COMPLETED · PHASE1
• Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer — COMPLETED · PHASE2
• Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone — TERMINATED · PHASE1
• TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) — TERMINATED · PHASE2
• A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients — OTHER · PHASE1
• ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer — COMPLETED · PHASE1
• A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer — COMPLETED · PHASE1
• Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer — COMPLETED · PHASE2
• Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer — COMPLETED · PHASE2
• PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer — WITHDRAWN
• Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer — COMPLETED · PHASE2
• Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer — COMPLETED · PHASE3
• Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer — OTHER · NA
• Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel — COMPLETED · PHASE2
• Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer — COMPLETED · PHASE1
• Study of Weekly Cabazitaxel for Advanced Prostate Cancer — COMPLETED · PHASE2
• Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy — TERMINATED · PHASE2
• A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) — TERMINATED · PHASE3
• An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer — COMPLETED · PHASE2
• Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel — COMPLETED · PHASE2
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer — COMPLETED · PHASE2
• Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate — COMPLETED · PHASE2
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer — TERMINATED · PHASE1
• Molecular Phenotype Changes and Personalized Treatment for CRPC — OTHER · NA
• Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy — COMPLETED · PHASE2
• Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy — COMPLETED · PHASE1
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — COMPLETED · PHASE3
• YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy — TERMINATED · PHASE2
• PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC — TERMINATED · PHASE2
• Radiotherapy vs Observation for CRPC — OTHER
• Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy — COMPLETED · PHASE1
• RNActive®-Derived Therapeutic Vaccine — TERMINATED · PHASE1
• A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients — COMPLETED · PHASE2
• A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer — TERMINATED · PHASE2
• A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer — COMPLETED · PHASE2
• Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer — COMPLETED · PHASE2

Refine this search